AC Immune SA ACIU

Company Overview

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company focused on developing precision medicines for neurodegenerative diseases associated with protein misfolding, including Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. The company operates within the biotechnology and central nervous system (CNS) therapeutics industries, with its core activities centered on research, development, and commercialization partnerships involving disease-modifying therapies and diagnostic technologies. According to publicly available disclosures including SEC filings and company investor materials, AC Immune’s primary revenue sources have historically consisted of collaboration agreements, licensing arrangements, milestone payments, and research funding tied to strategic pharmaceutical partnerships rather than commercial product sales.

The company’s technology platforms are designed to target toxic forms of proteins such as beta-amyloid, tau, and alpha-synuclein. AC Immune has developed multiple proprietary platforms, including antibody-based therapeutics, small molecules, and diagnostic imaging agents. Its strategic positioning is based on early-stage biomarker integration and precision medicine approaches intended to identify pathological protein conformations before extensive neurodegeneration occurs. Founded in 2003 and headquartered in Lausanne, Switzerland, AC Immune evolved from an academic-science-driven biotechnology company into a publicly traded clinical-stage enterprise listed on Nasdaq under the ticker ACIU.